ClinicalTrials.gg
CompletedNCT02515747PRELUDEUpdated Aug 5, 2015

Prospective Russian Evaluation of Lp(a) Role in cardiovascUlar DiseasE

An interventional study of percutaneous coronary intervention and coronary artery bypass grafting in Coronary Disease and Cardiovascular Diseases, sponsored by Russian Cardiology Research and Production Center. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-05.

Sponsored by Russian Cardiology Research and Production Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to explore the role of lipoprotein(a) and apolipoprotein(a) phenotype in fatal and non-fatal cardiovascular disease (CVD) events risk in coronary disease patients divided on the basis of management strategy - medical, endovascular or open cardiac surgery.

Read the detailed description

Between January 1993 and September 2006, we enrolled 1400 consecutive patients from the Atherosclerosis Department with known Lp(a) levels and coronary heart disease (CHD) verified by angiography. In accordance with clinical condition and angiography data were assigned them into three parallel treatment arms and followed up to 15 years. This study was conducted according to the principles of the Declaration of Helsinki and the Institutional Ethics Committee.

02

Conditions studied

  • Coronary Disease
  • Cardiovascular Diseases

Keywords

  • Lipoprotein(a)
  • coronary artery bypass grafting (CABG)
  • apo(a)
  • prognosis
  • myocardial infarction
  • cardiovascular death
  • percutaneous coronary intervention (PCI)
03

In context

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

This study's enrollment of 1,400 is above the median of 160 across 780 interventional studies indexed under Coronary Disease.

Browse Coronary Disease studies →

Lead sponsor

Russian Cardiology Research and Production Center is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • stable coronary heart disease verified by angiography

Exclusion criteria

Exclusion Criteria:

  • acute coronary syndromes,
  • acute infections,
  • inflammatory disease within 3 months prior to inclusion,
  • familial hypercholesterolemia,
  • triglycerides>4.5 mmol/L,
  • missing Lp(a) measurements
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,400 participants (actual)

Study arms

  • No intervention
    conservative treatment

    Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage

  • Active comparator
    percutaneous coronary intervention

    2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment

    Procedure: percutaneous coronary intervention

  • Active comparator
    coronary artery bypass grafting

    elective surgery myocardial revascularisation on the basement of drugs treatment

    Procedure: coronary artery bypass grafting

Interventions

  • Procedurepercutaneous coronary intervention

    elective percutaneous coronary balloon angioplasty and/or stenting

  • Procedurecoronary artery bypass grafting

    elective surgical myocardial revascularisation

06

What researchers measure

Primary outcomes

  1. non-fatal myocardial infarction and cardiovascular death

    we took a composite primary outcome measure because anticipated a low number of hard-end-points in each treatment arm

    Time frame: up to 15 years

Secondary outcomes

  1. non-fatal myocardial infarction and cardiovascular death and myocardial revascularisation and hospitalization for recurrent or unstable angina

    we chose a composite secondary outcome mesure as a standard for such type studies and to obtain a statistical difference between the groups

    Time frame: up to 15 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ezhov MV, Afanas'eva OI, Kambegova AA, Afanas'eva MI, Trukhacheva EP, Naumov VG, Pokrovskii SN. [The role of atherosclerosis risk factors in development of ischemic heart disease in young men]. Ter Arkh. 2009;81(5):50-4. Russian. PubMed 19537587 ↗
  • Ezhov MV, Liakishev AA, Pokrovskii SN. [Lipoprotein (a) - an independent risk factor in atherosclerosis]. Ter Arkh. 2001;73(9):76-82. No abstract available. Russian. PubMed 11642088 ↗
  • Pokrovsky SN, Ezhov MV, Il'ina LN, Afanasieva OI, Sinitsyn VY, Shiriaev AA, Akchurin RS. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003 Oct;126(4):1071-5. doi: 10.1016/s0022-5223(03)00365-9. PubMed 14566249 ↗
  • Ezhov MV, Safarova MC, Afanas'eva OI, Il'ina LN, Liakishev AA, Pokrovskii SN. [High level of lipoprotein (a) as a predictor of poor long-term prognosis after coronary artery bypass surgery]. Kardiologiia. 2011;51(1):18-22. Russian. PubMed 21626797 ↗
  • Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014 Aug;235(2):477-82. doi: 10.1016/j.atherosclerosis.2014.05.944. Epub 2014 Jun 4. PubMed 24952151 ↗
  • Britareva VV, Afanas'eva OI, Dobrovol'skii AB, Ezhov MV, Titaeva EV, Karpov IuA, Pokrovskii SN. [Lipoprotein(a) and Apo-A isoforms in patients with intermittent claudication]. Ter Arkh. 2002;74(12):49-52. Russian. PubMed 12577841 ↗
  • Ezhov MV, Afanas'eva OI, Benevolenskaia GF, Savchenko AP, Balakhonova TV, Liakishev AA, Pokrovskii SN. [Association of lipoprotein(a) and apolipoprotein(a) phenotypes with coronary and carotid atherosclerosis in CHD men]. Ter Arkh. 2000;72(1):28-32. Russian. PubMed 10687202 ↗
  • Ezhov MV, Afanas'ev OI, Benevolenskaia GF, Savchenko AP, Liakishev AA, Pokrovskii SN. [Lipoprotein(a) as a biochemical marker of coronary atherosclerosis]. Ter Arkh. 1997;69(9):31-4. Russian. PubMed 9411822 ↗
  • Safarova MS, Trukhacheva EP, Ezhov MV, Afanas'eva OI, Afanas'eva MI, Tripoten' MI, Liakishev AA, Pokrovskii SN. [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. Kardiologiia. 2011;51(5):9-16. Russian. PubMed 21649590 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1993, a primary completion of Sep 2006 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2015
First posted
Aug 5, 2015
Start
Jan 1993
Primary completionActual
Sep 2006
CompletionActual
Jan 2014
Last update
Aug 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02515747
Lead sponsor
Russian Cardiology Research and Production Center
Responsible party
Marat Vladislavovich Ezhov (MV Ezhov, MD, PhD, DMSc) (Associate Professor, Dr., Russian Cardiology Research and Production Center) — Principal investigator
First posted
Aug 5, 2015
Start date
Jan 1993
Primary completion
Sep 2006
Completion
Jan 2014
Last update
Aug 5, 2015

Study contacts

Marat V. Ezhov, PhD, DMSc
principal investigator · Russian Cardiology Research and Production Center
Sergei N. Pokrovsky, PhD, DSc
study chair · Russian Cardiology Research and Production Center
Valery V. Kukharchuk, PhD, DMSc
study chair · Russian Cardiology Research and Production Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion